PERKINELMER INC Stock Price, News & Analysis

The Board of Directors of PerkinElmer (NYSE: PKI) announced a quarterly dividend of $0.07 per share, payable on May 7, 2021. Shareholders on record as of April 16, 2021 will receive this dividend. PerkinElmer, a leader in health innovation, reported revenues of approximately $2.9 billion in 2019 and employs around 14,000 people globally, serving customers in 190 countries. The company is also a component of the S&P 500 Index.

PerkinElmer (NYSE:PKI) announced that its New Coronavirus Nucleic Acid Detection Kit has received Emergency Use Authorization (EUA) from the FDA for testing asymptomatic individuals. A significant finding indicates that nearly 60% of COVID-19 transmissions originate from asymptomatic carriers, highlighting the need for effective diagnostic testing. This test boasts the lowest Limit of Detection among authorized COVID-19 tests, making it highly sensitive. The company also offers sample pooling options, enhancing testing capabilities without additional resources.

PerkinElmer (NYSE: PKI) projects 66% reported and 63% organic revenue growth for Q4 2020, with GAAP EPS of at least $2.88 and adjusted EPS of at least $3.60. This robust performance is mainly due to increased demand for COVID-19 solutions, generating approximately $535 million in revenue. However, the non-COVID-19 segment saw a 3% organic decline. The financial results will be released on February 2, 2021, followed by a conference call at 5:00 p.m. ET.

PerkinElmer will acquire Oxford Immunotec for $22.00 per share, valuing the deal at approximately $591 million. This acquisition, expected to close by mid-2021, represents a premium of 28.3% compared to Oxford Immunotec's last closing price and significantly enhances PerkinElmer's portfolio in infectious disease testing, particularly for tuberculosis. PerkinElmer anticipates the deal to be modestly accretive to earnings in the first year and expects Oxford Immunotec's sales growth to outpace its own Diagnostics franchise. Oxford Immunotec will become a privately held company post-acquisition.

PerkinElmer (NYSE: PKI) has announced its participation in the J.P. Morgan Healthcare Conference on January 11, 2021, at 7:30 a.m. ET. CEO Prahlad Singh will present updates on the company’s strategic priorities. The presentation will be accessible via a live audio webcast on PerkinElmer's investor relations website, with a replay available for 90 days post-event. In 2019, PerkinElmer generated approximately $2.9 billion in revenue and operates globally with about 14,000 employees.

PerkinElmer (NYSE: PKI) announced the launch of the Anti-SARS-CoV-2 QuantiVac^TM ELISA (IgG) by its subsidiary EUROIMMUN, a quantitative test for IgG antibodies against the SARS-CoV-2 S1 antigen. This assay supports vaccine development and may help assess immunity in previously infected individuals. EUROIMMUN aims to file for FDA Emergency Use Authorization (EUA). Production capacity has increased to over three million tests weekly, facilitating significant contributions to global epidemiological studies.

PerkinElmer (NYSE: PKI) will participate in the Wolfe Virtual Healthcare Conference on November 19 at 11:25 a.m. ET. The company's CEO, Prahlad Singh, is set to provide an update on the company's strategic priorities. A live audio webcast can be accessed through the Investors section of PerkinElmer's website, where a replay will also be available for 90 days after the event. PerkinElmer reported approximately $2.9 billion in revenue in 2019, employing about 13,000 people globally.

PerkinElmer, a leader in health innovation, announced its participation in the Stifel Virtual Healthcare Conference on November 17, 2020, at 1:20 p.m. ET. Jamey Mock, SVP and CFO, will discuss the company's strategic priorities and updates. A live audio webcast will be accessible on the company’s Investors webpage, with a replay available for 90 days post-event. In 2019, PerkinElmer reported revenues of approximately $2.9 billion and has a workforce of around 13,000 employees across 190 countries.

PerkinElmer (NYSE: PKI) has announced a recommended all-cash offer to acquire Horizon Discovery Group (LSE: HZD) for approximately $383 million. This acquisition, expected to close in Q1 2021, aims to enhance PerkinElmer's life sciences portfolio with gene editing and gene modulation tools. Horizon, headquartered in the UK, generated $75.5 million in revenue in 2019 and specializes in CRISPR and RNAi technologies. PerkinElmer anticipates the acquisition will modestly boost non-GAAP earnings in the first year and position Horizon favorably in a growing market.